Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 ...

Gliflozins, another name for sodium-glucose cotransporter-2 (SGLT2) inhibitors, were the subject of the investigation. By ...

A specific class of diabetes drug appears to lower people's risk for dementia and Parkinson's disease, a new study shows.

A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a study ...

The cause of Parkinson's Disease remains largely unknown, but a new drug could be extremely beneficial to treat symptoms.

Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk ...

Increased exposure to air pollution in the form of particulate matter with a diameter of 2.5 µm or less (PM2.5) and nitrogen ...

According to a new study, certain diabetes medications may significantly reduce this risk. These drugs, called gliflozins or ...

A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a new study. A class of drugs for diabetes may be associated with a lower risk ...

A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a study published in the September 18, 2024, online issue of Neurology.